These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 34888660)

  • 1. Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis.
    Virseda-Berdices A; Brochado-Kith O; Díez C; Hontañon V; Berenguer J; González-García J; Rojo D; Fernández-Rodríguez A; Ibañez-Samaniego L; Llop-Herrera E; Olveira A; Perez-Latorre L; Barbas C; Rava M; Resino S; Jiménez-Sousa MA
    J Antimicrob Chemother; 2022 Feb; 77(3):719-726. PubMed ID: 34888660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
    J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis.
    Díez C; Berenguer J; Ibañez-Samaniego L; Llop E; Pérez-Latorre L; Catalina MV; Hontañón V; Jiménez-Sousa MA; Aldámiz-Echevarría T; Martínez J; Calleja JL; Albillos A; Bellón JM; Resino S; González-García J; Bañares R
    Clin Infect Dis; 2020 Dec; 71(10):2726-2729. PubMed ID: 32386053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
    Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
    J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy.
    Puente Á; Cabezas J; López Arias MJ; Fortea JI; Arias MT; Estébanez Á; Casafont F; Fábrega E; Crespo J
    Rev Esp Enferm Dig; 2017 Jan; 109(1):17-25. PubMed ID: 27990835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
    Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
    J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
    Reiberger T; Rutter K; Ferlitsch A; Payer BA; Hofer H; Beinhardt S; Kundi M; Ferenci P; Gangl A; Trauner M; Peck-Radosavljevic M
    Clin Gastroenterol Hepatol; 2011 Jul; 9(7):602-8.e1. PubMed ID: 21397726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.
    Schwabl P; Mandorfer M; Steiner S; Scheiner B; Chromy D; Herac M; Bucsics T; Hayden H; Grabmeier-Pfistershammer K; Ferlitsch A; Oberhuber G; Trauner M; Peck-Radosavljevic M; Reiberger T
    Aliment Pharmacol Ther; 2017 Jan; 45(1):139-149. PubMed ID: 27910154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.
    Roberts S; Gordon A; McLean C; Pedersen J; Bowden S; Thomson K; Angus P
    Clin Gastroenterol Hepatol; 2007 Aug; 5(8):932-7. PubMed ID: 17544878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of betablocked patients after sustained virological response in hepatitis C cirrhosis.
    Abadía M; Montes ML; Ponce D; Froilán C; Romero M; Poza J; Hernández T; Fernández-Martos R; Olveira A;
    World J Gastroenterol; 2019 Jun; 25(21):2665-2674. PubMed ID: 31210717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
    Reiberger T; Payer BA; Ferlitsch A; Sieghart W; Breitenecker F; Aichelburg MC; Schmied B; Rieger A; Trauner M; Peck-Radosavljevic M;
    Antivir Ther; 2012; 17(7):1327-34. PubMed ID: 22948263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
    Lens S; Rincón D; García-Retortillo M; Albillos A; Calleja JL; Bañares R; Abraldes JG; Bosch J; Sanchez-Tapias JM; Forns X; García-Pagán JC
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1846-1853.e1. PubMed ID: 25912838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study.
    Colecchia A; Colli A; Casazza G; Mandolesi D; Schiumerini R; Reggiani LB; Marasco G; Taddia M; Lisotti A; Mazzella G; Di Biase AR; Golfieri R; Pinzani M; Festi D
    J Hepatol; 2014 Jun; 60(6):1158-64. PubMed ID: 24607624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
    Mandorfer M; Kozbial K; Schwabl P; Freissmuth C; Schwarzer R; Stern R; Chromy D; Stättermayer AF; Reiberger T; Beinhardt S; Sieghart W; Trauner M; Hofer H; Ferlitsch A; Ferenci P; Peck-Radosavljevic M
    J Hepatol; 2016 Oct; 65(4):692-699. PubMed ID: 27242316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study.
    Knop V; Hoppe D; Vermehren J; Troetschler S; Herrmann E; Vermehren A; Friedrich-Rust M; Sarrazin C; Trebicka J; Zeuzem S; Welker MW
    J Viral Hepat; 2021 Nov; 28(11):1604-1613. PubMed ID: 34342081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
    Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
    J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.
    Brochado-Kith Ó; Martínez I; Berenguer J; González-García J; Salgüero S; Sepúlveda-Crespo D; Díez C; Hontañón V; Ibañez-Samaniego L; Pérez-Latorre L; Fernández-Rodríguez A; Ángeles Jiménez-Sousa M; Resino S
    Front Immunol; 2021; 12():723196. PubMed ID: 34497613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis.
    Rincon D; Ripoll C; Lo Iacono O; Salcedo M; Catalina MV; Alvarez E; Nuñez O; Matilla AM; Clemente G; Bañares R
    Am J Gastroenterol; 2006 Oct; 101(10):2269-74. PubMed ID: 17032192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
    Mandorfer M; Kozbial K; Freissmuth C; Schwabl P; Stättermayer AF; Reiberger T; Beinhardt S; Schwarzer R; Trauner M; Ferlitsch A; Hofer H; Peck-Radosavljevic M; Ferenci P
    Aliment Pharmacol Ther; 2015 Sep; 42(6):707-18. PubMed ID: 26179884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.